Venetoclax

Venetoclax is an orally administered targeted anticancer medicine belonging to the class of B-cell lymphoma 2, or BCL-2, inhibitors. BCL-2 is a protein that helps certain cancer cells avoid programmed cell death, allowing abnormal lymphoid or myeloid cells to survive for longer than normal. Venetoclax selectively binds to BCL-2 and inhibits its activity, allowing the natural process of programmed cell death to occur in susceptible cancer cells. It is primarily used in hematological malignancies, particularly chronic lymphocytic leukemia and small lymphocytic lymphoma, and in combination with other medicines for certain adults with newly diagnosed acute myeloid leukemia who are not candidates for intensive induction chemotherapy. Venetoclax is available as oral tablets and is generally taken once daily with food and water. Treatment schedules and combinations depend on the specific disease, previous treatment, patient characteristics and applicable regulatory approval. Because rapid destruction of leukemia cells can cause tumor lysis syndrome, treatment initiation requires structured dose escalation and preventive measures in appropriate patients. Blood counts and infection risk also require ongoing monitoring. Venetoclax has become clinically important because it directly targets a survival pathway used by malignant blood cells and can be incorporated into fixed-duration or combination treatment strategies in selected patients.

Venetoclax was developed as a selective inhibitor of the BCL-2 protein, with its development focused initially on BCL-2-dependent hematological malignancies. The U.S. Food and Drug Administration granted accelerated approval in April 2016 for certain patients with chronic lymphocytic leukemia with 17p deletion who had received at least one prior therapy. Subsequent FDA approvals expanded its use to broader CLL and small lymphocytic lymphoma populations and to acute myeloid leukemia in combination with azacitidine, decitabine or low-dose cytarabine for specified adults who are 75 years or older or who have comorbidities that preclude intensive induction chemotherapy. The European Union granted conditional marketing authorisation for Venclyxto in December 2016, which was converted to a standard marketing authorisation in November 2018. European indications have subsequently expanded to include additional combination regimens for previously untreated CLL and treatment of newly diagnosed AML in adults who are ineligible for intensive chemotherapy. In India, CDSCO records show approval of venetoclax tablets in 10 mg, 50 mg and 100 mg strengths in April 2025. Major clinical development programmes include MURANO, CLL14, VIALE-A and VIALE-C, together with other studies evaluating venetoclax in CLL, SLL and AML.

Venetoclax is used primarily in chronic lymphocytic leukemia and small lymphocytic lymphoma and in combination regimens for selected patients with acute myeloid leukemia. In CLL and SLL, venetoclax may be used alone in selected treatment settings or in combination with medicines such as obinutuzumab, rituximab, ibrutinib or acalabrutinib depending on the patient's previous treatment, disease characteristics and regulatory jurisdiction. In the United States, venetoclax is indicated for adults with CLL or SLL and for newly diagnosed AML in adults aged 75 years or older or those with comorbidities that preclude intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine. In Europe, approved CLL uses include combination treatment in previously untreated disease and combination with rituximab after at least one previous therapy, as well as selected monotherapy settings involving 17p deletion or TP53 mutation or previous failure of specified treatment classes. Venetoclax is not generally used as a routine monotherapy for newly diagnosed AML and is administered with an approved hypomethylating agent or low-dose cytarabine according to the applicable indication.

Venetoclax is taken orally once daily with a meal and water. In CLL or SLL, treatment is initiated using a gradual five-week dose ramp-up to reduce the risk of tumor lysis syndrome, generally progressing from 20 mg daily during week one to 50 mg during week two, 100 mg during week three, 200 mg during week four and 400 mg during week five, after which the recommended daily dose is generally 400 mg when used as monotherapy or in specified combination regimens. Combination schedules can differ, and some regimens have defined treatment durations such as 12 months with obinutuzumab or 24 months with rituximab-based treatment according to the approved regimen. For AML, venetoclax is initiated using a shorter dose escalation and is generally continued at 400 mg once daily after ramp-up when used with azacitidine or decitabine, while a lower daily dose is used with low-dose cytarabine. The AML regimen is administered in repeated treatment cycles, with treatment continuing according to response, tolerability and clinical assessment. Dose interruptions or modifications may be required for neutropenia, infections, tumor lysis syndrome or drug interactions. Patients with severe hepatic impairment require dose reduction, and interaction-related dose modifications may be necessary.

Common side effects of venetoclax vary according to the underlying disease and combination regimen. Frequently reported effects include neutropenia, thrombocytopenia, anemia, nausea, diarrhoea, constipation, vomiting, fatigue, headache, decreased appetite and infections. In patients with AML, low blood counts and febrile neutropenia are particularly important because venetoclax is commonly administered with other treatments that can also suppress bone marrow function. Laboratory abnormalities involving blood counts, electrolytes, liver function or other parameters may occur during treatment. Many adverse effects can be managed with dose interruptions, supportive treatment and appropriate monitoring, but persistent fever, signs of infection, unusual bleeding or other new symptoms require prompt medical assessment.

Tumor lysis syndrome is a major risk associated with venetoclax, particularly during treatment initiation and dose escalation in patients with a high tumor burden. Rapid destruction of malignant cells can cause metabolic abnormalities and potentially serious kidney or cardiac complications. Appropriate risk assessment, hydration, uric-acid-lowering treatment and laboratory monitoring are therefore important during initiation and escalation. Severe or prolonged neutropenia can occur and may increase the risk of serious infections, while thrombocytopenia and anemia can also require treatment interruption or supportive care. Serious infections, including pneumonia and sepsis, have been reported. Venetoclax can also cause embryo-fetal toxicity and should not be used during pregnancy unless specifically determined to be appropriate by the treating healthcare professional. Concomitant use with certain CYP3A inhibitors can substantially increase venetoclax exposure and requires contraindication or dose adjustment depending on the treatment phase and strength of the interaction.

Before treatment, clinicians should assess tumor burden and the patient's risk of tumor lysis syndrome, together with renal function, blood counts and relevant biochemical parameters. During the initial dose escalation, laboratory monitoring should be performed at intervals appropriate to the patient's tumor lysis risk, and higher-risk patients may require more intensive monitoring or inpatient management. Venetoclax is extensively affected by medicines that inhibit or induce CYP3A and P-glycoprotein. Strong or moderate CYP3A inhibitors and P-gp inhibitors may require venetoclax dose modification, while strong or moderate CYP3A inducers should generally be avoided because they can reduce venetoclax exposure. Strong CYP3A inhibitors are contraindicated during initiation and ramp-up in patients with CLL or SLL. Venetoclax can also affect exposure to certain P-gp substrates, so appropriate separation or monitoring may be required. Live attenuated vaccines should not be administered before, during or after treatment until B-cell recovery as specified in prescribing information. Patients with severe hepatic impairment require additional dose adjustment.

Prescribers should establish the exact indication, treatment combination and disease burden before initiating venetoclax because the dose escalation, treatment duration and monitoring requirements differ between CLL, SLL and AML. Tumor lysis risk should be assessed before the first dose and reassessed during dose escalation, with appropriate hydration, uric-acid-lowering prophylaxis and laboratory monitoring. A complete medication review is essential because CYP3A inhibitors and inducers can produce clinically important changes in venetoclax exposure. During ongoing treatment, complete blood counts should be monitored regularly, particularly when significant neutropenia or thrombocytopenia is expected. In AML, clinicians should also coordinate venetoclax with the selected hypomethylating agent or low-dose cytarabine and consider treatment interruptions or cycle modifications according to blood-count recovery and clinical status. Pharmacists should reinforce administration with food and water, verify dose-escalation schedules and interaction-related modifications, and counsel patients to report fever, infection symptoms, unusual bleeding or other concerning symptoms promptly.